1-3 of 3
Julie S. Larsen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)

Amanda F Cashen, MD, Gary J. Schiller, MD, FACP, Margaret R. O’Donnell, MD, Julie S. Larsen, PharmD, Akhil Baranwal, MD, Michael T Cullen, MD, John F DiPersio, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 560.
https://doi.org/10.1182/blood.V112.11.560.560
Published: 2008
Journal Articles

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS).

David P. Steensma, MD, Maria R. Baer, MD, James L. Slack, MD, Rena Buckstein, MD, Lucy Godley, MD, PhD, Julie S. Larsen, Michael T. Cullen, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2007) 110 (11): 1450.
https://doi.org/10.1182/blood.V110.11.1450.1450
Published: 2007
Journal Articles

Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML).

Amanda Cashen, MD, Gary J. Schiller, MD, Julie S. Larsen, PharmD, Michael T. Cullen, Jr., MD, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1984.
https://doi.org/10.1182/blood.V108.11.1984.1984
Published: 2006